Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COH06 +/- Atezolizumab in Refractory Non-Small Cell Lung Cancer
NCT05334329Phase 1Active, not recruiting
- Sponsor
- University of California, Irvine
- Start
- Jul 2022
- Primary completion
- Nov 2028
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of COH06 in non-small cell lung cancer (NSCLC), sponsored by University of California, Irvine. Primary endpoints: Incidence of adverse events - CTCAE at 2 years, Incidence of adverse events - ASTCT at 2 years and 1 more. Started Jul 2022; status: active, not recruiting.
02
Drugs
COH06
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05334329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05334329.